VBI-S for the Treatment of Hypotension in Hypovolemic Septic Shock Patients

Inclusion criteria: 1. Male or female at least 18 years of age 2. Evidence of bacterial infection demonstrated by positive blood culture and/or a known source of infection or an elevated procalcitonin of ≥ 2 ng/ml. 3. Patient has a mean blood pressure \< 65 mmHg that is unresponsive to fluids currently available on the market. 4. Sequential Organ Failure Assessment (SOFA) score \>= 5. 5. Sepsis diagnosis: The presence of infection which can be proven or suspected by 2 or more of the following criteria: * Lactate \> 2 mmol/L * Mottled skin * Decreased capillary refill of nail beds or skin * Fever \> 38.3˚C, or 101˚F * Hypothermia \< 36˚C core temperature (\<96.8˚F) * Heart rate \> 90 * Tachypnea * Change in mental status * Significant edema or positive fluid balance (\>20 mL/kg over 24 hours) * Hyperglycemia (\>140 mg/dL) in someone without diabetes * White blood cell count \>12,000 or less than 4,000, or with \>10% "bands" (immature * forms) * Elevated C-reactive protein in serum (according to your lab's cutoffs) * Elevated procalcitonin in serum (≥ 2 ng/ml) * Arterial hypoxemia (PaO2/FiO2 \< 300) * Acute drop in urine output (\<0.5 ml/kg/hr for at least 2 hours despite fluid resuscitation, or about 30 ml/hour for a 70 kg person) * Creatinine increase \> 0.5 mg/dL * INR \> 1.5 or aPTT \> 60 seconds * Absent bowel sounds (ileus) * High bilirubin (total bilirubin \> 4 mg/dL Exclusion Criteria: 1. Patients with a ventricular assist device 2. Acute coronary syndrome 3. Pregnant 4. Bronchospasm 5. Mesenteric ischemia 6. Emergency surgery 7. Acute liver disease (Hepatitis B and C as examples) 8. Liver failure with a Model for End-Stage Liver Disease (MELD) score ≥ 19 9. Hematologic or coagulation disorders including thrombocytopenia (platelet count \<50,000) and associated with hemodynamically significant active bleeding. 10. Absolute neutrophil count of \< 1000 mm3 11. Current participation or participation in another experimental or device study within the last 30 days before the start of this study. Patient may be included if on other drugs for COVID-19 and or septic shock 12. Patients with a known allergy to soybeans or eggs 13. Patient is hypervolemic as assessed by CVP, ultrasound, Swan Ganz catheter, Flo-Trac, esophageal doppler, bioimpedance, ECHO, Partial carbon dioxide rebreathing (NICO), lithium dilution (LIDCO) or other method published in a peer reviewed journal